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Abstract
In order to eliminate health disparities in the United States, more efforts are needed to address
the breadth of social issues directly contributing to the healthy divide observed across racial and
ethnic groups. Socioeconomic status, education, and the environment are intimately linked to
health outcomes. However, with the tremendous advances in technology and increased
investigation into human genetic variation, genomics is poised to play a valuable role in bolstering
efforts to find new treatments and preventions for chronic conditions and diseases that disparately
affect certain ethnic groups. Promising studies focused on understanding the genetic underpinnings
of diseases such as prostate cancer or beta-blocker treatments for heart failure are illustrative of
the positive contribution that genomics can have on improving minority health.
Background
Disparities or inequities in health refer to socio-demo-
graphic group differences in the distribution of disease,
health outcomes, or access to health care. In the United
States, there is overwhelming evidence for the existence of
disparities in health when ethnic minority groups (as
defined by the Office of Management and Budget [1] but
referred to here as ethnicities [2]) are compared to their
white counterparts[3] (Figure 1). A number of factors play
a significant role in varying health outcomes, which
include, but are not limited to, socio-political structure,
discrimination, cultural practices (e.g., diet), socioeco-
nomic status, exposure to harmful toxins in the environ-
ment, and access to health care.
The battle against eliminating ethnic health disparities in
the United States begins, and perhaps ends, at the social
level. Therefore, one may question the relevance and util-
ity of a genetics lens as a means to view these disparities.
By focusing on new insights on the global pattern of
human genetic variation (HGV), made possible by the
successful completion of the International HapMap
Project [4] and ongoing sequencing efforts of individual
genomes, this article will provide important illustrations
of how genomics may inform our understanding of pop-
ulation differences in disease distribution and variable
drug response.
Human genetic variation: Understanding our 
similarities and differences
In order to appreciate the sources of HGV, it is important
to understand the common and unique histories of
human populations. Fossil evidence dates the rise of
Homo sapiens at approximately 200,000 years ago [5-7].
Although the migration known as the out-of-Africa the-
ory[8,9] took place approximately 80,000 years ago (Fig-
ure 2), many experts would consider all Homo sapiens to be
Africans as recent as 36,000 years ago (modern humans
had already reached as far as Europe and Australia by this
point) based on evidence from cranial analysis and dating
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of a Late Pleistocene human skull [10]. As modern
humans spread throughout the world, the frequency of
genetic variations varied from region to region as a result
of random chance, natural selection, and other genetic
mechanisms[11]. In short, our diversity, genetic or other-
wise, is not an illusion. It is intimately associated with our
journey within and out of Africa and it is the foundation
of our uniqueness: from physical characteristics to disease
susceptibility or resistance.
Genetic variations can occur at different frequencies in dif-
ferent populations, especially when those populations are
widely separated and unlikely to exchange much genetic
material through mating. Interestingly, the most recently
arising variants have not had enough time to spread
widely beyond the population and geographic region in
which they originated. For this reason, there must remain
a consistent link between HGV and the historic and cul-
tural experiences of human populations as we look to
understand differential disease distribution and variable
drug response.
Human genetic variation and disease
From a biological perspective, the genetic underpinnings
of many diseases remain to be described in complete
detail or at all. It is rare to stumble across scenarios in
which mistakes in the genetic alphabet are contained
within a single gene and lead to a specific disease. Sickle
cell disease, cystic fibrosis, fragile-X syndrome, Hunting-
ton's disease, and other single-gene disorders affect less
than two percent of the general population. These diseases
often have a simple and predictable inheritance pattern
and their manifestation is largely independent of social
determinants. Unfortunately, it is now clear that the for-
mula for identifying the underlying cause for common
diseases (e.g., diabetes, heart disease, and cancer) is more
complex than the examples mentioned above. However,
the common theme remains that these diseases are
genetic in nature, triggered or influenced in varying
degrees by non-genetic forces such as diet, stress, or expo-
sures to harmful agents in the environment.
There have been a number of scientific advancements
made in the past decade that allow for our genetic code to
Death rates of selected ethnicities for six causes of death in the United States Figure 1
Death rates of selected ethnicities for six causes of death in the United States. Rates are per 100,000 population 
and age-adjusted to the 2000 census. AI = American Indian, AN = Alaska Native, PI = Pacific Islander. Source: Health, United 
States, 2007.
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be analyzed at a fantastic rate, which yields faster and
more accurate identification of genetic mutations [12].
Information garnered from such analyses has tremendous
potential to lend insight into the genetic mechanisms of
disease and disease susceptibility. For example, the agnos-
tic search of thousands of human genomes (e.g., genome-
wide association studies – GWAS) is rapidly shedding
light on subsets of genetic variants that are associated with
an increase risk of particular conditions[13,14]. These
findings can also provide clarification on the pervasive-
ness of different genetic variants across or within ethnic
groups, which can potentially influence the way we treat
and diagnose disease. We present working examples of the
potential impact of genomics on variable drug response
and disparities in health at the individual and group lev-
els.
Group and individual identity in the genomic era: 
Lessons from variable response to drugs
The Centers for Disease Control and Prevention recog-
nizes cardiovascular disease as a condition that dispropor-
tionately affects ethnic minorities. The 2007 National
Center for Health Statistics report shows that African
Americans have the highest rate of hypertension when
compared to Hispanic or White populations in the United
States [3]. Hypertension, in turn, has been identified as a
significant risk factor for stroke and myocardial infarction,
which can often lead to cardiac failure and ischemia. The
statistics are sobering: almost 300,000 Americans die
from heart failure every year [3] and one out of four heart
failure patients dies within a year of diagnosis and one out
of two within five years [15,16]. Socioeconomic indica-
tors such as income and educational levels are powerful
predictors but fall short of completely explaining the inci-
dence of this disease in different populations [17].
From the clinical perspective, the standard care for treat-
ing heart failure is administration of beta-adrenergic
receptor (betaAR) blocking agents, or beta-blockers, that
act by suppressing the action of the hormone adrenaline.
However, over the past several years the medical commu-
nity found it difficult to arrive at a consensus on the effi-
cacy of beta-blockers in African Americans. Confounding
reports between 1999 and 2002 added to the confusion of
Human migration pattern from Africa to Asia, Australia, Europe, and North and South America Figure 2
Human migration pattern from Africa to Asia, Australia, Europe, and North and South America. Selected arti-
facts found around the world (1–5) are examples of evidence supporting the out-of-Africa theory. Reprinted with permission 
from 5W Infographics.BMC Medical Genomics 2009, 2:29 http://www.biomedcentral.com/1755-8794/2/29
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whether race played a role or not in how individuals
responded to beta-blockers and the medical community
was left to rely on anecdotal or inconclusive evidence [18-
22].
Last year, Stephen Liggett and colleagues provided a
genetic explanation for the perceived disparate health out-
comes observed among African Americans following the
administration of beta-blockers [23]. The authors pub-
lished a well-designed study that revealed a nonsynony-
mous polymorphism in the G protein-coupled receptor
kinase 5 (i.e., leucine is substituted for glutamine at posi-
tion 41) which they showed confers a "natural genetic
beta-blockade." Individuals that carry this variant (GRK5-
Leu41) have an increased survival rate against cardiac fail-
ure and ischemia when compared to those without the
protective mutation when no betaAR antagonists are
administered. Moreover, the difference in time to cardiac
transplant or mortality was not significant when compar-
ing GRK5-Leu41 individuals to patients who received
beta-blockers but did not carry the protective variant.
Support for Liggett and colleagues' conclusions stems
from the comprehensive nature of their approach. The
authors employed sequencing and genotyping, pharma-
cogenomics, transgenic mouse models, rigorous statistical
analysis, and robust human study protocols to describe
and ultimately confirm the genetic rationale for the con-
fusing efficacy of beta-blockers in African Americans.
However, the take-home message goes beyond genetic
sleuthing. The findings provide meaningful evidence to
support the need for a paradigm shift (i.e., genetic profil-
ing in clinical trials) as treatments move closer to individ-
ualized medicine. Group labels such as African Americans
fall short as a reliable predictor for how a member of this
group will respond to medications such as beta-blockers.
In essence, having the protective variant is not a defining
characteristic of African Americans since only a propor-
tion, approximately 40%, carry it. African Americans who
do not carry this variant derive significant benefits from
beta-blockers in the treatment of heart failure. Therefore,
the end result of classifying and subsequently treating
African Americans as one uniform group is an unclear and
misrepresented interpretation of beta-blocker efficacy,
which potentially puts a majority of African Americans at
risk of not receiving the proper treatment. The confusion
on whether or not beta-blockers are effective in African
Americans highlights a prevailing notion, among the
medical and scientific communities alike, that the group
"African American" is genetically and culturally homoge-
nous.
The problem of using group data as a proxy for individu-
als in the context of drug response is not limited to histor-
ically-labeled admixed populations such as African
Americans. This point was demonstrated clearly in a
recent commentary by Ng and colleagues [24]. The exam-
ination of the complete sequence of the personal genomes
of two Caucasian men (J. Craig Venter [25] and James
Watson [26]) revealed that the group label "White" or
"Caucasian" was inadequate in predicting their metabolic
status with respect to key drug-metabolizing genes. This
observation underscores the need to know individual
genetic variants instead of relying on a patient's appear-
ance or self-identified ethnicity.
Genomics and health disparities: Lessons from 
the genetics of prostate cancer
Prostate cancer provides another striking example of eth-
nic minorities disproportionately affected by disease. In
the United States, an estimated 186,000 new cases for
prostate cancer tops the 2008 list of incident cancer cases
in men [27]. Moreover, African-American men unequally
share the burden of this disease, which is illustrated both
in incidence and in mortality (approximately 1.6- and
2.4-fold higher than European Americans, respectively)
[27]. Numerous reports have indicated that disparities
exist in treatment and access to adequate health care,
which ultimately contribute to disparities in mortality
rates [28]; of note, breast cancer mortality is higher in Afri-
can-American women despite a greater incidence in Euro-
pean American women [29]. It is therefore critically
important to approach the problem of group differences
in complex disease susceptibility in a comprehensive
manner.
In the case of prostate cancer, genetics provides compel-
ling, though preliminary data on the potential role of
molecular factors in explaining the significant unbalanced
incidence of prostate cancer in African-American and
potentially other men from populations of the African
diaspora. Several independent studies have identified and
replicated genomic regions that contain risk variants for
prostate cancer in multiple human populations [30-33]. A
locus on chromosome 8, specifically 8q24, has reproduc-
ibly been associated with prostate cancer in men from sev-
eral ancestral backgrounds including Europeans, Africans,
Latinos, and Japanese [34]. The impact of these suscepti-
bility variants on prostate cancer varies significantly with
ancestry ranging from population attributable risks (PAR)
of 8% to 68% [33]; the PAR is defined as the number (or
proportion) of cases that would not occur if the risk factor
were eliminated. Interestingly, the PAR for all identified
variants in the 8q24 region is 32% in European Americans
and 68% in African Americans. If functional studies con-
firm these alleles as "true" susceptibility variants, the
observed differences in allele frequencies and PAR
between Europeans and African Americans may explain a
significant proportion of the disparity in prostate cancer
incidence between the two groups. It is important to pointBMC Medical Genomics 2009, 2:29 http://www.biomedcentral.com/1755-8794/2/29
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out that none of the genetic variants identified in the 8q24
region lie within known genes or alter the coding
sequence of an encoded protein [34].
The examples described in this section are not of rare or
obscure diseases. The impact of these diseases on our gen-
eral population is severe and the disproportionate impact
on subgroups within the population is, by definition,
unequal. Genetics must continue to play a significant role
alongside social and behavioral research and social service
programs and initiatives.
Genomics, group identity and health disparities
Genomics research has much to offer in the global effort
to understand disease susceptibility and resistance at the
individual and population levels [35]. However, genetics
and, by association, genomics are certainly not immune
to producing a certain level of controversy and confusion
with respect to the communication and interpretation of
data. In the fervor of discovery, researchers at times forget
or, perhaps, they do not feel it is their obligation, to take
a step back and put their work in an appropriate context.
Finding a novel mechanism associated with a biochemical
pathway can be equally important as linking genetic vari-
ants to disease susceptibility; however, the parallels may
end when viewed from a social perspective.
Microarrays spotted with hundreds of thousands of
human single nucleotide polymorphisms and high-
throughput sequencing and genotyping efforts have all
contributed to the vast amounts of data that are literally
streaming into research laboratories for analysis [36].
Population-genetics studies have turned from a science du
jour to a necessary and integral part of how we identify
disease susceptibility among populations with ancestry
from different parts of the world. The trend is in part dic-
tated by technology, which only seems to be getting faster
and cheaper. The pace of progress shows no sign of slow-
ing down and the stream of information will only get
broader. However, we cannot shy away from the potential
pitfalls that inherently lurk when assumptions and con-
jecture are hazily combined with empirical data especially
since these pitfalls are potentially larger and deeper when
comparisons across ethnic groups are involved.
Lohmueller et al. recently published a population-based
study that investigated the abundance of deleterious
mutations found among European and African popula-
tions [37]. Their findings led them to conclude that Euro-
pean Americans have acquired genetic variations
considered to be harmful in greater number when com-
pared to African Americans. The classification of "possibly
damaging" and "probably damaging" prompted disagree-
ment among other researchers not involved in the study.
While the discrepancy in interpretation may be nuanced,
the potential impact of misinterpreting the broader state-
ments made on these different populations appears far
greater when put in a social setting. We do not expect the
authors to be at fault for nonsensical arguments based on
poor generalizations. However, the larger point is that
health disparities are so heavily rooted in social structure
that the distribution and dissemination of genomic data
must acknowledge the broader context in order to com-
prehensively educate both the scientific community and
the public.
Conclusion
Health disparities are a global phenomena by no means
limited to the United States. The social determinants that
feed these health inequalities and inequities [39,40] are
undeniable. Geoffrey Rose, a revered epidemiologist
whose insight furthered our current understanding of
public health, is often cited for his exclamation to search
for the "causes of the causes". Many have justly viewed
this statement as a challenge to change public policy and
a call for an equal and fair distribution of societal
resources. While a sigh of relief is pending, we can find
solace in knowing that much of what continues to widen
the healthy divide – poor education, substandard living
and working conditions, limited access to affordable
healthcare – is reversible. However, the origin of health
differences is indeed complex and biology cannot be left
out of the discussion if we are to understand why some
individuals get certain diseases and others do not or why
some respond to treatment differently. To that end, the
contributions of genetics and genomics should not be
viewed as a distraction but, rather, as a positive addition
to the collective efforts in eliminating health disparities
globally.
In the search to understand biology's role in health differ-
ences, the scientific community, particularly genetic and
genomic investigators, should make considerable effort to
interpret their data regarding group differences within the
context of the historic experiences of these groups. It is
also important to recognize the challenge posed by the
use of "race" in biomedical research. The use of social
group labels such as African American, Hispanics, and
Asians are likely to be insufficient to get us to where we
need to be as we strive towards individualized medicine.
For this reason, the emphasis falls squarely on the study of
human genetic variation. As mentioned previously [2],
understanding the detailed structure of human genetic
variation may help to deconstruct imprecise group defini-
tions currently applied in biomedical research and avoid
unintended consequences of generalizing biological char-
acteristics across these groups (e.g., beta-blocker efficacy).
If we use genomic information correctly, we will simulta-
neously describe our similarities and differences withoutBMC Medical Genomics 2009, 2:29 http://www.biomedcentral.com/1755-8794/2/29
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reaffirming old prejudices. More importantly, the careful
unbiased study and interpretation of the human story
coded in our DNA will enable us to appreciate the fact that
individuals cannot be treated as a representative for all
those who physically resemble them or who share some
of their ancestry. The human genome is a mosaic of our
experiences, past and present.
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